The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000138.5(FBN1):c.1825C>T (p.Arg609Cys)

CA045974

439709 (ClinVar)

Gene: FBN1
Condition: Marfan syndrome
Inheritance Mode: Autosomal dominant inheritance
UUID: 06957bbd-fcab-4025-9669-eef8057aa2d6
Approved on: 2023-11-16
Published on: 2023-11-16

HGVS expressions

NM_000138.5:c.1825C>T
NM_000138.5(FBN1):c.1825C>T (p.Arg609Cys)
NC_000015.10:g.48508594G>A
CM000677.2:g.48508594G>A
NC_000015.9:g.48800791G>A
CM000677.1:g.48800791G>A
NC_000015.8:g.46588083G>A
NG_008805.2:g.142195C>T
ENST00000684448.1:n.499C>T
ENST00000316623.10:c.1825C>T
ENST00000316623.9:c.1825C>T
ENST00000537463.6:c.636+29117C>T
NM_000138.4:c.1825C>T

Uncertain Significance

Met criteria codes 3
PP3 PM1 BS1
Not Met criteria codes 19
PS2 PS1 PS3 PS4 PP1 PP4 PP2 PM6 PM2 PM3 PM5 PM4 BA1 BS2 BS4 BS3 BP2 BP3 BP4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
FBN1 VCEP
NM_00138 c.1825C>T is a missense variant in FBN1 predicted to cause a substitution of an arginine by cysteine at amino acid 609 (p.Arg609Cys). This variant was found in a proband with thoracic aortic aneurysm and dissection (TAAD) and a proband with minor skeletal features (PMID: 32154576; Bichat internal data). This variant is present in gnomAD (BS1; 2/18384 [0.011%] East Asian alleles; https://gnomad.broadinstitute.org/). It has been submitted to ClinVar twice, once as likely pathogenic and once as of uncertain significance (Variation ID: 439709). This variant introduces a novel cysteine residue which may impede the normal formation of critical disulfide bridges (PM1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein’s structure or function (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: Due to the conflicting and insufficient evidence, this variant is classified as uncertain significance for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: BS1, PM1, PP3.
Met criteria codes
PP3
REVEL = 0.930
PM1
Cysteine-creating variant
BS1
Highest MAF: 2/18384 (0.011%, East Asian) in gnomAD v2.1.1
Not Met criteria codes
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4
BS1 met so PS4 is n/a at any strength per FBN1 VCEP specifications
PP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
n/a because of presence of evidence toward benign (BS1) per FBN1 VCEP specifications
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.